苑东生物(688513.SH)：布瑞哌唑片获得药品注册证书

Core Viewpoint - Yuan Dong Biotechnology (688513.SH) has received the drug registration certificate from the National Medical Products Administration (NMPA) for its drug, Brexpiprazole tablets, which are indicated for the treatment of adult schizophrenia [1] Group 1: Product Development - Brexpiprazole tablets contain the active ingredient Brexpiprazole and were originally developed by Otsuka Pharmaceutical Co., Ltd. [1] - The drug was approved for marketing in the United States in July 2015 under the brand name Rexulti® and is expected to be imported into China by June 2024 [1] Group 2: Market Position - Currently, the only available product in the domestic market is the imported original drug, and Yuan Dong's product is the first domestically approved generic drug under the new registration classification, which is considered to have passed the consistency evaluation [1]